The plant, in the city of Nanning in Guangxi province, has been set up in collaboration with a European pharmaceutical company for which Evonik is expected to produce various active ingredients under a multi-year supply contract and in compliance with cGMP (current Good Manufacturing Practices), the pharmaceutical industry’s chief quality assurance guidelines.
Evonik Industries said that to strengthen ties with local authorities and neighbors, it followed the official startup of the Nanning plant with an open house day. This is already something of a tradition, being the fifth time in succession that Evonik has opened one of its Chinese production sites to the public to provide information on its activities and strengthen the Responsible Care initiative.
Hans-Josef Ritzert, head of exclusive synthesis and amino acids business line at Evonik, said: “That would not have been possible without the excellent support of the administration of the autonomous province of Guanxi, the city of Nanning, and Wuming district.
“The new plant is an expression of our horizontal integration strategy. With this plant we will further consolidate our position as a high performing partner for exclusive synthesis.”